Prospective Observational Cohort Study to Evaluate the Benefits, Documented in the Experimental Settings, of Treatment With SGLT2-i in Normal Clinical Practice, in Subjects With Type 2 Diabetes and Older Than 70 Years. (SOLDMiDiab02)

NCT05477017 UNKNOWN

The aim of the study is to evaluate the benefits, documented in experimental settings, of treatment with SGLT2-i in subjects with type 2 diabetes and older than 70 years in normal clinical practice. The type of study does not involve immediate risks or direct benefits for the subjects taking part in it. The potential benefits for clinicians and healthcare systems are: greater knowledge of diabetic disease and the study of new treatment options. However, the analysis of the data will allow us to better identify which patients benefit most from treatment with glycosurics.

Details

Lead sponsor	University of Milan
Status	UNKNOWN
Enrolment	800
Start date	2022-09
Completion	2023-03

Conditions

• Type2Diabetes

Interventions

• SGLT2 inhibitor

Primary outcomes

• Variation in HbA1c values (% -point) — From Baseline to 12 months
  Variation in HbA1c values (% -point) from baseline to 12 months from enrollment

Countries

Italy